NATO Pharma Bags Tentative US FDA Approval for Olaparib, Targeting $1.4 Billion Market
Natco Pharma Limited (NSE: NATCOPHARM, BSE: 524816) has strengthened its oncology portfolio by securing tentative approval from the U.S. Food and Drug Administration (US FDA) for its generic Olaparib Tablets in 100 mg and 150 mg strengths. The approval marks another important milestone in the company’s strategy to expand its presence in the high-value U.S. generics market.
The Hyderabad-based pharmaceutical company will manufacture the product, while its marketing partner, Alembic Pharmaceuticals Limited, will distribute the generic drug in the United States once commercial launch becomes possible.
US FDA Grants Tentative Approval
The tentative approval covers generic versions of Olaparib Tablets 100 mg and 150 mg, which are bioequivalent to Lynparza®, the reference listed drug (RLD) marketed by AstraZeneca Pharmaceuticals.
Tentative approval indicates that the product has met the US FDA’s quality, safety, and efficacy requirements but cannot yet be commercially launched due to existing patent or exclusivity protections.
Key Highlights
- Product: Generic Olaparib Tablets
- Strengths: 100 mg and 150 mg
- Regulatory Status: US FDA Tentative Approval
- Reference Drug: Lynparza® (AstraZeneca Pharmaceuticals)
- Manufacturing: Natco Pharma Limited
- U.S. Distribution Partner: Alembic Pharmaceuticals Limited
- Estimated U.S. Market Size: Approximately USD 1.4 billion (12 months ended March 2026)
Large Opportunity in the Oncology Market
Olaparib is one of the leading targeted therapies used in the treatment of multiple cancers, including:
- Ovarian cancer
- Breast cancer
- Prostate cancer
- Pancreatic cancer
According to IQVIA data cited by the company, Lynparza® generated estimated U.S. sales of approximately USD 1.4 billion during the 12 months ended March 2026.
The sizeable market presents a significant commercial opportunity for Natco Pharma once the generic product becomes eligible for launch.
Partnership with Alembic Pharmaceuticals
Under the collaboration agreement, Natco Pharma will manufacture the generic Olaparib tablets, while Alembic Pharmaceuticals will manage commercialization and distribution across the U.S. market.
The partnership combines Natco’s manufacturing expertise with Alembic’s established distribution network in the United States.
Para IV Litigation Remains Pending
The company noted that Paragraph IV (Para IV) patent litigation relating to Olaparib remains ongoing.
As a result, the US FDA has granted only tentative approval at this stage. Commercial launch will depend on the resolution of the patent litigation or the expiry of applicable patent and exclusivity periods.
Investors are likely to closely monitor future legal developments, as a favorable outcome could pave the way for the product’s market launch.